Ozempic Gastroparesis Settlement: Understanding the Statute of Limitations in Texas

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Specific Legal Context

The legacy of general health and science information has long provided a foundation for public understanding of medication risks and legal recourse. Within this framework, the transition from broad health education to specific product liability concerns requires careful contextualization. The widespread use of Ozempic, initially approved for diabetes management, has expanded into public discourse regarding potential adverse effects, including gastroparesis. This shift reflects a natural progression from general health awareness to focused inquiry about individual exposure scenarios. In Texas, the statute of limitations for filing claims related to Ozempic and gastroparesis becomes a critical consideration for those who have used the medication. The occupational exposure concern arises not from workplace settings but from the patient’s direct exposure to the drug through prescription use. This exposure, while therapeutic in intent, may lead to unintended health consequences that prompt legal evaluation. The bridge from general health context to Ozempic exposure and gastroparesis risk thus hinges on recognizing how routine medical treatment can intersect with legal timelines. Understanding the statute of limitations in Texas requires acknowledging the date of injury discovery, which may be linked to when symptoms of gastroparesis first manifest. This transition underscores the importance of moving from general health literacy to specific legal awareness regarding medication exposure.

Ozempic and Gastroparesis: The Medical Evidence

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes. Its pharmacological action slows gastric emptying, a mechanism that can contribute to gastrointestinal adverse effects. Among these, gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction—has been reported in association with Ozempic use. Clinical presentation of gastroparesis includes nausea, vomiting, early satiety, bloating, and abdominal pain, which overlap with common Ozempic side effects but may persist or worsen after dose stabilization. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of nausea, vomiting, and diarrhea reports occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions was higher with Ozempic 0.5 mg (3.1%) and 1 mg (3.8%) compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently with 2 mg (34.0%) versus 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal reactions with frequency <5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal adverse events, though gastroparesis specifically is not listed as a distinct adverse reaction in the label.

Mechanistic Link and Risk Context

The mechanistic pathway linking Ozempic to gastroparesis involves GLP-1 receptor agonist-induced delay in gastric emptying. Semaglutide slows gastric motility, which can exacerbate or unmask underlying gastroparesis. In susceptible individuals, prolonged use may lead to symptomatic gastroparesis requiring medical intervention. The label does not include a specific warning for gastroparesis, though it notes hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The absence of a dedicated gastroparesis warning raises questions about the adequacy of risk communication to patients and prescribers. For patients in Texas considering legal action related to Ozempic-associated gastroparesis, the statute of limitations is a critical factor. Texas law generally allows two years from the date of injury or discovery of harm for personal injury claims. However, the timeline between Ozempic exposure and documented gastroparesis symptoms can be variable. Gastrointestinal adverse reactions often emerge during dose escalation, but gastroparesis may develop insidiously over weeks to months. Patients who experienced persistent nausea, vomiting, or abdominal pain after starting Ozempic should document the onset and progression of symptoms, as this evidence is essential for establishing a causal link and meeting statutory deadlines. Settlement-related considerations for affected patients include the need to demonstrate that Ozempic caused or contributed to gastroparesis, that the manufacturer failed to provide adequate warnings, and that the harm resulted in compensable damages such as medical expenses, lost wages, and pain and suffering. The label’s listing of gastrointestinal adverse reactions without specific mention of gastroparesis may be used to argue that warnings were insufficient. However, the label does note that gastrointestinal reactions were common and led to discontinuation, which could be interpreted as general awareness of risk. In summary, the evidence shows a clear association between Ozempic and gastrointestinal adverse reactions, including those consistent with gastroparesis. The mechanistic plausibility is supported by the drug’s effect on gastric emptying. Patients in Texas must be aware of the two-year statute of limitations and should seek legal counsel promptly to preserve their rights. Documentation of symptom onset, medical records, and Ozempic prescription history are crucial for any potential claim.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Texas?

In Texas, the statute of limitations for personal injury claims, including those related to Ozempic-induced gastroparesis, is generally two years from the date of injury or discovery of harm. This means that affected individuals must file their lawsuit within two years of when they knew or should have known that Ozempic caused their gastroparesis. It is crucial to consult with an attorney promptly to ensure compliance with this deadline.

How can I prove that Ozempic caused my gastroparesis?

To establish a causal link between Ozempic and gastroparesis, you will need medical records documenting your Ozempic prescription, the onset and progression of symptoms such as nausea, vomiting, and abdominal pain, and a diagnosis of gastroparesis from a healthcare provider. Evidence that symptoms began after starting Ozempic and that other causes were ruled out can strengthen your claim. Additionally, referencing clinical trial data showing increased gastrointestinal adverse events with Ozempic (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166) may support causation.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.